In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Best of the Blog: IN VIVO, September 2008

Executive Summary

Highlights of our blog coverage for September 2008 included ongoing coverage of the financial crisis and how the broader financial woes may manifest in the world of healthcare financing.

You may also be interested in...

The Alzheimer's Divide

Issues of clinical trial design are at the forefront in Alzheimer's drug development. Researchers and investors are weighing the impact of late-stage failures, even as significant unknowns remain about disease mechanism and the correlation of biochemical markers and clinical effects. A fundamental question hangs over AD drug development, which is unique in many respects: in deciding how to move from Phase II into Phase III, what can you know and how can you know it?

Alzheimer's Development Financing: Risky Therapies Call for Innovative Deals

Eli Lilly has hedged its bets on its two late-stage Alzheimer's disease candidates. In a deal with TPG-Axon and Quintiles' partnering group NovaQuest, Lilly sheds risk (and potentially reward) in this notoriously difficult therapeutic space. A model for private equity / pharma deals going forward?

Running Late: FDA Review Timelines Lengthen For New Product Applications

FDA is missing more new drug review deadlines: at least seven in the first eight months of this year. The experiences of those delayed applications indicate some interesting ways to interpret what it means when a user fee date comes and goes without an FDA decision. One clear observation: the longer a sponsor has to wait after the user fee deadline, the worse the likely result.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts